Citizens Reiterates Market Outperform on Immix Biopharma, Maintains $23 Price Target

Benzinga Newsdesk www.benzinga.com Negative 95.0%

Neg 95% Neu 0% Pos 0%

Citizens analyst Reni J. Benjamin reiterates Immix Biopharma (NASDAQ:IMMX) with a Market Outperform and maintains $23 price target.